Columbia Laboratories Acquires Molecular Profiles

Article

Columbia Laboratories acquires Molecular Profiles in multimillion-dollar deal.

Columbia Laboratories has acquired Molecular Profiles, a UK-based pharmaceutical development services company, for approximately $25 million.

This acquisition was unanimously approved by the boards of directors of both companies and received the approval of Molecular Profiles’ shareholders. No further approvals are anticipated to be required.

According to the company, Molecular Profiles’ recorded approximately $9 million in revenues for its fiscal year ended July 31, 2013.

Source: Columbia Laboratories

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content
Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept. | Image Credit: © Dilok - stock.adobe.com

CordenPharma and Viking Therapeutics to Partner for Integrated Supply of GLP-1s

Patrick Lavery
March 13th 2025
Article

The multi-year strategic partnership is intended to support commercial demand of Viking Therapeutics’ GLP-1 candidate, VK2735.

Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Jill Murphy
November 14th 2023
Podcast

In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

FDA Approves First Generics of Rivaroxaban Tablets

Patrick Lavery
March 12th 2025
Article

Rivaroxaban, long known under the brand name Xarelto, is an anticoagulant, a classification that is among the most-prescribed medications in the United States.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

New Almac Pharma Services Commercial Manufacturing Facility Opens in Northern Ireland

Patrick Lavery
March 11th 2025
Article

The company’s 100,000-sq.-ft. space is expected to enhance its capabilities for commercial oral dose treatment manufacturing in a variety of therapeutic areas.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Stäubli Robotics Previews World’s First Cleanroom Mobile Robot for INTERPHEX Display

Patrick Lavery
March 11th 2025
Article

Sterimove will make its North American debut at the April 1–3, 2025 event.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Noramco Group Establishes Sterile Injectable Manufacturing Capabilities with $25 Million Investment

Patrick Lavery
March 10th 2025
Article

The investment is intended for the Halo Pharma facility in Whippany, NJ, and aims to help relieve capacity shortages in the injectable supply chain in the United States.